GTBP - GT Biopharma Inc. Stock Price, Fair Value and News

3.75USD+0.10 (+2.74%)Market Closed

Market Summary

USD3.75+0.10

Market Closed

2.74%

GTBP Stock Price

View Fullscreen

GTBP RSI Chart

GTBP Valuation

Market Cap

5.0M

Price/Earnings (Trailing)

-0.66

Price/Sales (Trailing)

6.46

EV/EBITDA

-12.93

Price/Free Cashflow

-0.57

GTBP Price/Sales (Trailing)

GTBP Profitability

Operating Margin

100.00%

EBT Margin

-151.85%

Return on Equity

-101.62%

Return on Assets

-53.85%

Free Cashflow Yield

-176.61%

GTBP Fundamentals

GTBP Revenue

Revenue (TTM)

780.0K

GTBP Earnings

Earnings (TTM)

-7.6M

Earnings Growth (Yr)

46.96%

Earnings Growth (Qtr)

-22.6%

Breaking Down GTBP Revenue

Last 7 days

-5.4%

Last 30 days

-12.3%

Last 90 days

-47.7%

Trailing 12 Months

-70.7%

How does GTBP drawdown profile look like?

GTBP Financial Health

Current Ratio

2.12

GTBP Investor Care

Shares Dilution (1Y)

12.30%

Diluted EPS (TTM)

-10.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	414.0K	536.0K	658.0K	780.0K
2022	5.0M	3.5M	1.9M	292.0K
2021	0	0	8.2M	6.6M
2016	0	0	0	9.8M
2015	0	0	0	0
2014	0	0	0	0
2013	666.0K	990.0K	1.1M	875.0K
2012	0	131.3K	236.7K	342.0K
2011	0	16.0K	21.0K	26.0K
2010	0	0	0	11.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of GT Biopharma Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 11, 2023	breen michael martin	acquired	57,400	0.287	200,000	executive chairman/interim ceo
Aug 11, 2023	ohri manu	acquired	57,400	0.287	200,000	cfo & secretary
Aug 11, 2023	ohri manu	sold	-57,400	0.287	-200,000	cfo & secretary
Apr 11, 2023	breen michael martin	bought	25,000	0.5	50,000	executive chairman/interim ceo
Apr 06, 2023	ohri manu	bought	25,000	0.5	50,000	cfo & secretary
Jul 15, 2022	ohri manu	acquired	-	-	100,000	cfo & secretary
Jul 15, 2022	breen michael martin	acquired	-	-	278,058	exec. chair. and interim ceo
Jul 15, 2022	ohri manu	sold	-	-	-100,000	cfo & secretary

Which funds bought or sold GTBP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	new	-	47,449,000	47,449,000	0.09%
Apr 24, 2024	BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC	sold off	-100	-77.00	-	-%
Apr 24, 2024	BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC	new	-	44.00	44.00	-%
Apr 09, 2024	Welch Group, LLC	sold off	-100	-2,550	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.07	15,306	277,438	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	338	9,149	11,662	-%
Feb 15, 2024	Front Row Advisors LLC	sold off	-100	-14.00	-	-%
Feb 15, 2024	Front Row Advisors LLC	new	-	15.00	15.00	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	4,948	4,948	-%
Feb 14, 2024	Retirement Group, LLC	unchanged	-	-	11.00	-%

Are Funds Buying or Selling GTBP?

Are funds buying GTBP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GTBP

No. of Funds

Unveiling GT Biopharma Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	2,175,358	SC 13G/A
Sep 19, 2023	cytovance biologics inc	6.8%	2,755,817	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	3,676,186	SC 13G
Mar 03, 2022	bristol investment fund ltd	0%	0	SC 13G/A
Jan 28, 2022	bigger capital fund l p	-	0	SC 13G/A
Jan 18, 2022	alpha capital anstalt	867%	265,232	SC 13G/A
Feb 17, 2021	bigger capital fund l p	3.5%	729,029	SC 13G

Recent SEC filings of GT Biopharma Inc.

View All Filings

Date Filed	Form Type	Document
Mar 26, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 01, 2024	8-K	Current Report

Peers (Alternatives to GT Biopharma Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.39%	-19.31%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	5.41%	-4.57%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.99%	-29.65%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.3B	-	-14.83%	70.74%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-16.49%	-30.64%	-9.12	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.67%	-6.03%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-13.72%	-45.61%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-0.25%	294.45%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.06%	3.25%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	70.91%	57.98%	-0.22	2.14	-13.45%	66.37%

GT Biopharma Inc. News

Latest updates

GT Biopharma Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2013Q4
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	1,543,000	14,684,000	18,742,667	22,801,333	26,860,000	20,155,250	13,450,500	6,745,750	41,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20,000	7,000	-2,000	-2,000	11,000
Operating Expenses	-	-	-	-	-	-	-	-	-	52,504,500	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	3.0%	1,811,000	1,758,000	1,526,000	2,015,000	2,936,000	4,280,000	1,875,000	3,355,000	11,874,000	4,946,000	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-0.5%	1,357,000	1,364,000	2,095,000	1,650,000	2,842,000	2,743,000	1,139,000	2,087,000	6,304,000	1,008,000	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	1.4%	-1.50	-1.52	-1.52	-1.52	-1.52	-1.45	-1.45	-1.45	-1.45	-2.39	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	1,000	212,000	-	-	-	-	22,000	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-2,829,000	-3,630,000	1,543,000	14,684,000	-26,113,000	-1,692,000	26,860,000	-20,516,000	-18,655,000	-4,219,000	-
EBT Margin	0%	-1.52	-1.52	-1.52	-1.52	-1.52	-1.52	-1.52	-1.52	-1.52	-1.52	-	-	-	-	-	-	-	-	-	-	-
Net Income	-22.6%	-2,962,000	-2,416,000	-1,992,000	-227,000	-5,584,000	-6,881,000	-2,979,000	-5,440,000	-18,022,000	-5,453,000	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-831.0%	-9.74	-1.05	-1.50	-1.60	-2.14	-3.41	-3.27	-3.46	-5.94	-4.74	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-6.7%	-2,095,000	-1,964,000	-1,894,000	-2,906,000	-4,298,000	-2,918,000	-2,786,000	-5,215,000	-3,705,000	-3,929,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Assets	-12.6%	14.00	16.00	18.00	20.00	17.00	21.00	24.00	27.00	32.00	6.00	1.00	1.00	0.00	9.00	17.00	26.00	26.00	25.00	27.00	255	257
Current Assets	-12.4%	14.00	16.00	18.00	20.00	17.00	21.00	24.00	27.00	32.00	6.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	3.00
Cash Equivalents	-59.3%	1.00	3.00	3.00	2.00	6.00	2.00	5.00	7.00	9.00	5.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	3.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00
Liabilities	8.0%	7.00	6.00	6.00	7.00	5.00	5.00	9.00	10.00	10.00	27.00	31.00	-	21.00	20.00	19.00	17.00	16.00	14.00	13.00	9.00	5.00
Current Liabilities	30.3%	7.00	5.00	5.00	4.00	5.00	5.00	9.00	10.00	10.00	35.00	31.00	29.00	21.00	20.00	19.00	17.00	16.00	14.00	13.00	9.00	5.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	26.00	23.00	22.00	13.00	13.00	13.00	12.00	11.00	11.00	11.00	7.00	3.00
Shareholder's Equity	-25.3%	7.00	10.00	12.00	13.00	12.00	16.00	15.00	18.00	22.00	-	-	-	-	-	0.00	0.00	10.00	11.00	13.00	246	252
Retained Earnings	-0.4%	-682	-679	-676	-674	-674	-668	-662	-659	-653	-595	-589	-586	-569	-567	-565	-535	-533	-528	-524	-288	-279
Additional Paid-In Capital	0.1%	690	689	688	688	686	685	677	677	674	566	-559	559	548	548	548	545	543	540	538	535	532
Shares Outstanding	0.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-0.17	-0.17	-0.17	-0.17	-0.17	-0.17	-0.17	-0.17	-0.17	-0.17	-0.17	-0.17
Float	-	-	-	12.00	-	-	-	90.00	-	-	-	-	9.00	-	-	-	7.00	-	-	-	40.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-4.5%	-2,095	-2,005	-1,894	-2,906	-4,298	-2,918	-2,786	-5,215	-3,705	-3,929	-4,288	-3,684	-1,927	-1,701	-3,411	-223	-485	-1,126	-1,087	-961	-1,244
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	9,807	269	-147	147	-	-894	2,497	1,140	2,565	1,505
Cashflow From Investing	-74.1%	478	1,845	2,657	-6,989	7,506	25.00	1,081	3,533	2,991	-	-	-	-	-	-	-	-	200	-	-	-32.00
Cashflow From Financing	-	-	-	-	6,268	-1.00	-	-	-	-	137	16,238	25,942	6,874	1,200	4,257	200	200	975	1,300	952	104

GTBP Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Extinguishment of Debt [Line Items]
Revenues
Operating Expenses:
Research and development (including $0 and $718 of stock compensation to officers, directors and employees during the years ended December 31, 2023 and 2022, respectively)	6,466	8,811
Selling, general and administrative (including $2,200 and $3,903 of stock compensation to officers, directors and employees during the years ended December 31, 2023 and 2022, respectively)	7,110	12,446
Total Operating Expenses	13,576	21,257
Loss from Operations	(13,576)	(21,257)
Other (Income) Expense
Interest income	(780)	(292)
Interest expense	213	8
Change in fair value of warrant liability	(4,797)	(119)
Gain from extinguishment of debt
Unrealized (gain) loss-on marketable securities	(48)	30
Other	(20)
Total Other (Income) Expense	(5,979)	(373)
Net Loss	$ (7,597)	$ (20,884)
Net Loss Per Share - Basic	$ (5.64)	$ (19.66)
Net Loss Per Share - Diluted	$ (5.64)	$ (19.66)
Weighted average common shares outstanding - basic	1,347,713	1,062,267
Weighted average common shares outstanding - diluted	1,347,713	1,062,267
Share Settled Debt [Member]
Other (Income) Expense
Gain from extinguishment of debt	$ (547)

GTBP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 1,079	$ 5,672
Short-term investments	12,893	10,836
Prepaid expenses and other current assets	84	54
Total Current Assets	14,056	16,562
Operating lease right-of-use asset	53	165
Deposits		9
TOTAL ASSETS	14,109	16,736
Current liabilities
Accounts payable	4,328	3,140
Accrued expenses	1,195	1,669
Current operating lease liability	58	110
Warrant liability	1,052	19
Total Current Liabilities	6,633	4,938
Non-current operating lease liability		64
Total Liabilities	6,633	5,002
Stockholders’ Equity
Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized, Series C - 96,230 shares issued and outstanding at December 31, 2023 and 2022, respectively	1	1
Common stock, par value $0.001, 250,000,000 shares authorized, 1,380,633 shares and 1,090,748 shares issued and outstanding at December 31, 2023 and 2022, respectively	1	33
Additional paid in capital	689,539	686,168
Accumulated deficit	(682,065)	(674,468)
Total Stockholders’ Equity	7,476	11,734
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 14,109	$ 16,736

About GT Biopharma Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

CEO	Mr. Michael Martin Breen
WEBSITE	gtbiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	2

GT Biopharma Inc. Frequently Asked Questions

What is the ticker symbol for GT Biopharma Inc.? What does GTBP stand for in stocks?

GTBP is the stock ticker symbol of GT Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GT Biopharma Inc. (GTBP)?

As of Wed Apr 24 2024, market cap of GT Biopharma Inc. is 5.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GTBP stock?

You can check GTBP's fair value in chart for subscribers.

What is the fair value of GTBP stock?

You can check GTBP's fair value in chart for subscribers. The fair value of GT Biopharma Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GT Biopharma Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GTBP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GT Biopharma Inc. a good stock to buy?

The fair value guage provides a quick view whether GTBP is over valued or under valued. Whether GT Biopharma Inc. is cheap or expensive depends on the assumptions which impact GT Biopharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GTBP.

What is GT Biopharma Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, GTBP's PE ratio (Price to Earnings) is -0.66 and Price to Sales (PS) ratio is 6.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GTBP PE ratio will change depending on the future growth rate expectations of investors.